Unknown PHASE3 INTERVENTIONAL 2-arm NCT02502331

Safety and Immunogenicity of a New Formulation of Euvichol®

A Randomized, Observer Blinded, Controlled Trial to Evaluate the Safety and Immunogenicity of a New Formulation of Euvichol® (Killed Bivalent Whole Cell Oral Cholera Vaccine Manufactured by EuBiologics Co. Ltd.) in Healthy Individuals

Sponsor: EuBiologics Co.,Ltd

Conditions Cholera

Interventions Euvichol® Test Oral Cholera Vaccine

Updated 6 times since 2017 Last updated: Dec 15, 2015 Started: Mar 31, 2016 Primary completion: Jun 30, 2016 Completion: Aug 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Cholera, this trial is ongoing. The trial is conducted by EuBiologics Co.,Ltd and has accumulated 6 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE3

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE3
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE3
Feb 2018 — Jun 2018 [monthly]

Unknown Status PHASE3

Status: Not Yet Recruiting → Unknown Status

▶ Show 1 earlier version

Jan 2017 — Feb 2018 [monthly]

Not Yet Recruiting PHASE3

First recorded

Mar 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

EuBiologics Co.,Ltd
International Vaccine Institute

Data source: International Vaccine Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.